The announcement of a Type-B meeting with the FDA specifically for discussing commercial manufacturing planning of CAP-1002 indicates significant progress towards regulatory approval. This meeting is a critical step in expediting the BLA pathway, which could lead to a faster market entry for CAP-1002 in treating Duchenne Muscular Dystrophy. Given the importance of regulatory milestones in the biotech industry, this news is likely to be viewed positively by investors, potentially leading to an increase in CAPR's stock price in the short term.